Home » Topics » Science » New compound

New compound
RSS

HTL-0041178 shows efficacy in models of psychosis and cognitive impairment

Sep. 16, 2021

New potent and selective USP7 inhibitor S-205474 presented

Sep. 16, 2021

ZDWX-25, GSK-3beta/DYRK1A dual inhibitor with promising activity in models of AD

Sep. 15, 2021

fMLP receptor promotes inflammatory brain injury

Sep. 10, 2021

HA-344 shows promise for treating cutaneous metastatic melanoma

Sep. 10, 2021

Novel virulence factor LasB inhibitors for the treatment of P. aeruginosa infections

Sep. 10, 2021

Discovery of novel antibiotic class of tethered macrocyclic peptides

Sep. 10, 2021

NIH develops PET radioligands targeting CSF-1R for neuroinflammation

Sep. 9, 2021

GABA-A alpha5 PAM RO-7015738 presented for neurological disorders

Sep. 9, 2021

[44Sc]Sc-B28110 shows preclinical promise as a radiotracer for the imaging of prostate cancer

Sep. 8, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 11, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Wuxi Apptec insists it’s ‘not a Chinese military company’
BioWorld
Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military...
Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
BioWorld Science
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.